Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer

Aim: The role of regional nodal irradiation (RNI) after preoperative systemic treatment (PST) with targeted therapy for HER2-positive breast cancer remains uncertain. This study aimed to investigate the impact of RNI on locoregional recurrence (LRR) and disease-free survival (DFS) outcomes after doc...

Full description

Bibliographic Details
Main Authors:	Nalee Kim, Ji-Yeon Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Byung Joo Chae, Sei Kyung Lee, Jai-Min Ryu, Yeon Hee Park, Haeyoung Kim
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Breast
Subjects:	Radiation therapy HER2-positive breast cancer Neoadjuvant Anti-HER2 targeted therapy Primary systemic therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623005702

Similar Items

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer
by: Junghoon Shin, et al.
Published: (2023-09-01)

Generation and Characterization of Trastuzumab/Pertuzumab-Resistant HER2-Positive Breast Cancer Cell Lines
by: Marta Sanz-Álvarez, et al.
Published: (2023-12-01)

Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
by: Nalee Kim, et al.
Published: (2023-10-01)

Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland
by: Agnieszka Irena Jagiełło-Gruszfeld, et al.
Published: (2022-02-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

Suppression of Platelet-Derived Growth Factor Receptor-Alpha Overcomes Resistance to Trastuzumab through STAT3-Dependent IL-6 Reduction in HER2-Positive Breast Cancer Cells
by: Sangmin Kim, et al.
Published: (2023-02-01)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
by: Babak Nami, et al.
Published: (2019-03-01)

A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer
by: Dongdong Xu, et al.
Published: (2024-02-01)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
by: Hyehyun Jeong, et al.
Published: (2021-01-01)

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION
by: E. V. Lubennikova, et al.
Published: (2017-11-01)

Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
by: Soong June Bae, et al.
Published: (2024-02-01)

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
by: Page E. Blas, et al.
Published: (2024-03-01)

The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
by: Woong Ki Park, et al.
Published: (2023-11-01)

Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022-06-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain
by: Victor L. Cruz, et al.
Published: (2023-07-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Editorial: Cancer treatment and early detection targeting HER receptors, Volume II
by: Xiaoqing Cai, et al.
Published: (2023-06-01)

Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
by: Guang Ma, et al.
Published: (2023-09-01)

Radionuclide Therapy of HER2-Expressing Xenografts Using [<sup>177</sup>Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
by: Yongsheng Liu, et al.
Published: (2023-04-01)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
by: Xiaoyun Liu, et al.
Published: (2022-09-01)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
by: Sung Hoon Sim, et al.
Published: (2022-10-01)

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
by: Manuel Gámez-Chiachio, et al.
Published: (2022-09-01)

Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
by: Lu Liu, et al.
Published: (2023-12-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
by: Moslem Afrakhteh, et al.
Published: (2017-11-01)

Doxorubicin- and Trastuzumab-Modified Gold Nanoparticles as Potential Multimodal Agents for Targeted Therapy of HER2+ Cancers
by: Kinga Żelechowska-Matysiak, et al.
Published: (2023-03-01)

Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1
by: Supusson Pengnam, et al.
Published: (2023-10-01)

Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
by: Patrik Pöschke, et al.
Published: (2023-09-01)

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
by: Ji-Yeon Kim, et al.
Published: (2023-06-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

Enhanced Immunogenicity of Engineered HER2 Antigens Potentiates Antitumor Immune Responses
by: Insu Jeon, et al.
Published: (2020-07-01)

The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results
by: Kenji Nakano
Published: (2023-11-01)

Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC
by: Lőrinc Nagy, et al.
Published: (2024-03-01)

Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence
by: Kamel Debbi, et al.
Published: (2023-04-01)

Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy
by: Alexey Goltsov, et al.
Published: (2014-06-01)

Targeting HER2 expression in cancer: New drugs and new indications
by: Semir Vranić, et al.
Published: (2021-02-01)

Novel HER-2 Targeted Therapies in Breast Cancer
by: Catarina Lopes Fernandes, et al.
Published: (2023-12-01)